TY - JOUR
T1 - Diabetes, obesity, and breast cancer
AU - Kang, Chifei
AU - LeRoith, Derek
AU - Gallagher, Emily J.
N1 - Funding Information:
Financial Support: This work was supported by National Cancer Institute Grants R01CA128799 and R01CA200553 to D.L. and K08CA190770 to E.J.G.
Publisher Copyright:
© 2018 Endocrine Society
PY - 2018
Y1 - 2018
N2 - The rates of obesity and diabetes are increasing worldwide, whereas the age of onset for both obesity and diabetes are decreasing steadily. Obesity and diabetes are associated with multiple factors that contribute to the increased risk of a number of different cancers, including breast cancer. These factors are hyperinsulinemia, elevated IGFs, hyperglycemia, dyslipidemia, adipokines, inflammatory cytokines, and the gut microbiome. In this review, we discuss the current understanding of the complex signaling pathways underlying these multiple factors involved in the obesity/diabetes-breast cancer link, with a focus particularly on the roles of the insulin/IGF system and dyslipidemia in preclinical breast cancer models. We review some of the therapeutic strategies to target these metabolic derangements in cancer. Future research directions and potential therapeutic strategies are also discussed.
AB - The rates of obesity and diabetes are increasing worldwide, whereas the age of onset for both obesity and diabetes are decreasing steadily. Obesity and diabetes are associated with multiple factors that contribute to the increased risk of a number of different cancers, including breast cancer. These factors are hyperinsulinemia, elevated IGFs, hyperglycemia, dyslipidemia, adipokines, inflammatory cytokines, and the gut microbiome. In this review, we discuss the current understanding of the complex signaling pathways underlying these multiple factors involved in the obesity/diabetes-breast cancer link, with a focus particularly on the roles of the insulin/IGF system and dyslipidemia in preclinical breast cancer models. We review some of the therapeutic strategies to target these metabolic derangements in cancer. Future research directions and potential therapeutic strategies are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85055613020&partnerID=8YFLogxK
U2 - 10.1210/en.2018-00574
DO - 10.1210/en.2018-00574
M3 - Review article
C2 - 30215698
AN - SCOPUS:85055613020
SN - 0013-7227
VL - 159
SP - 3801
EP - 3812
JO - Endocrinology
JF - Endocrinology
IS - 11
ER -